Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China · Delayed Price · Currency is CNY 50.66
+0.56 (1.12%)
At close: Feb 3, 2026
SHE:301096 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -188.27 | -52.74 | 271.97 | 194.16 | 111.09 | 57.4 |
Depreciation & Amortization | 144.26 | 144.26 | 90.6 | 64.49 | 35.48 | 16.83 |
Other Amortization | 1.9 | 1.9 | 3.89 | 11 | 8.62 | 4.89 |
Loss (Gain) From Sale of Assets | - | - | -0.78 | -0.02 | - | - |
Asset Writedown & Restructuring Costs | 0.01 | 0.01 | 0.03 | 0.03 | 4.67 | 2.2 |
Loss (Gain) From Sale of Investments | 5.59 | 5.59 | 0.11 | 1.06 | 0.65 | -0.96 |
Provision & Write-off of Bad Debts | 38.07 | 38.07 | 21.63 | 9.16 | - | - |
Other Operating Activities | 158.59 | 19.79 | 7.64 | 3.8 | 2.98 | 0.29 |
Change in Accounts Receivable | -252.41 | -252.41 | -399.31 | -125.29 | -100.21 | -59.67 |
Change in Inventory | -88.2 | -88.2 | -28.55 | -43.2 | -19.23 | -1.1 |
Change in Accounts Payable | 3.26 | 3.26 | 78.49 | 135.25 | 109.86 | 26.4 |
Change in Other Net Operating Assets | -28.27 | -28.27 | 44.69 | 35.2 | 3.83 | 11.64 |
Operating Cash Flow | -192.59 | -195.86 | 90.45 | 259.41 | 145.42 | 54.36 |
Operating Cash Flow Growth | - | - | -65.13% | 78.38% | 167.52% | -23.94% |
Capital Expenditures | -86.39 | -395.1 | -688.6 | -591.58 | -248.45 | -255.12 |
Sale of Property, Plant & Equipment | -2.7 | - | 0.23 | 0.55 | 0.02 | - |
Cash Acquisitions | - | -13.43 | - | - | - | - |
Divestitures | - | - | 45.98 | - | - | - |
Investment in Securities | -138.34 | -143.46 | -52.29 | -76.12 | - | -1.5 |
Other Investing Activities | 137.83 | 87.45 | -72.73 | -23.72 | -2.73 | 0.83 |
Investing Cash Flow | -89.59 | -464.54 | -767.42 | -690.87 | -251.16 | -255.79 |
Long-Term Debt Issued | - | 1,244 | 469 | 300 | 131.75 | 163.22 |
Total Debt Issued | 1,397 | 1,244 | 469 | 300 | 131.75 | 163.22 |
Long-Term Debt Repaid | - | -905.93 | -103.07 | -575.6 | -19 | -9 |
Total Debt Repaid | -962.51 | -905.93 | -103.07 | -575.6 | -19 | -9 |
Net Debt Issued (Repaid) | 434.21 | 338.41 | 365.93 | -275.6 | 112.75 | 154.22 |
Issuance of Common Stock | 8.89 | 8.89 | 21.98 | - | 1,891 | - |
Repurchase of Common Stock | - | - | -50 | - | - | - |
Common Dividends Paid | -20.12 | -48.77 | -92.81 | -66.55 | -10.13 | -8.73 |
Other Financing Activities | -9.35 | -0.44 | -0.62 | -24.32 | -11.13 | -0.28 |
Financing Cash Flow | 413.63 | 298.09 | 244.48 | -366.48 | 1,982 | 145.21 |
Foreign Exchange Rate Adjustments | 0.32 | 0.01 | -0.13 | - | - | - |
Net Cash Flow | 131.77 | -362.29 | -432.62 | -797.93 | 1,876 | -56.21 |
Free Cash Flow | -278.98 | -590.96 | -598.15 | -332.16 | -103.02 | -200.76 |
Free Cash Flow Margin | -47.26% | -73.69% | -58.79% | -54.68% | -27.52% | -96.87% |
Free Cash Flow Per Share | -2.71 | -5.49 | -5.52 | -3.06 | -1.27 | -2.48 |
Cash Interest Paid | 0.43 | 0.43 | 0.41 | - | - | - |
Cash Income Tax Paid | 2.24 | -5.26 | 0.95 | -41.84 | 16.83 | 9.02 |
Levered Free Cash Flow | -271.93 | -796.21 | -550.77 | -520.34 | -104.48 | -221.74 |
Unlevered Free Cash Flow | -259.28 | -785.62 | -546.39 | -519.52 | -102.19 | -221.34 |
Change in Working Capital | -352.73 | -352.73 | -304.63 | -24.27 | -18.06 | -26.3 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.